EN DE

Oxiquim S.A (OXIQUIM) Fair Value & Analysis

Basic Materials · CL · Market cap 299B CLP

OS Oxiquim S.A OXIQUIM · SN
Price12,441 CLP
Fair Value14,742 CLP
Upside+18.5%
Quality62/100
Watch Oxiquim S.A for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Solidly profitable · 10.4% net margin
Low debt · generates free cash flow
8.72% dividend yield
Ranks above peers (8/10)
Moderate moat 59/100
Evidence: High Range 9,503 CLP – 21,136 CLP Share as image

Fair value as of: Jul 18, 2026

From 24 valuation models · updated 23 days ago

A solid business, screening 19% undervalued on our models.

What matters now

  • A fairly wide model range (9,503 CLP to 21,136 CLP) leaves room in how you read the outcome.
  • Our model range runs from 9,503 CLP (bear) to 21,136 CLP (bull), base 14,742 CLP. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 62/100 (solid quality) with high evidence: the data supports the verdict.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

12,849 CLP 750.52 CLP Fair Value 14,742 CLP Jul 2015 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.

How to read this chart

60‑month range 750.52 CLP – 12,849 CLP · fair‑value band 9,503 CLP – 21,136 CLP · the 12,441 CLP price screens below the 14,742 CLP fair value. Dashed = 300-day average. As of Jul 18, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Oxiquim S.A (OXIQUIM) currently trades at 12,441 CLP, while our model-based Fair Value estimate is 14,742 CLP, implying the stock looks roughly 18.5% undervalued today. The Quality Score stands at 62/100 (solid quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Oxiquim S.A generated revenue of 228B CLP at a net margin of 10.4%. Revenue declined 14.6% year over year. It earns a return on equity of 19.0%. Net debt stands at 47.1B CLP. Fundamentals as of Jul 18, 2026

Our scenario range runs from 9,503 CLP (bear case) to 21,136 CLP (bull case); at 12,441 CLP, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 4% below its 52-week high and 46% above its 52-week low, currently above its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -46% fair-value upside, at 19%, OXIQUIM screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 10,604 CLP 16,537 CLP 25,499 CLP 80
Residual Income 7,138 CLP 9,489 CLP 43,402 CLP 76
Rev-Margin DCF 9,360 CLP 15,396 CLP 22,361 CLP 74
All 24 models by family
DCF Models
FCF DCF 10,378 CLP 17,043 CLP 27,758 CLP 38
Owner Earnings 7,478 CLP 12,398 CLP 20,308 CLP 31
5Y Revenue Exit 9,360 CLP 15,385 CLP 23,063 CLP 39
5Y EBITDA Exit 9,185 CLP 15,057 CLP 21,866 CLP 41
5Y P/E Exit 10,943 CLP 18,355 CLP 26,136 CLP 38
10Y Revenue Exit 9,297 CLP 14,979 CLP 22,600 CLP 36
10Y EBITDA Exit 9,503 CLP 14,746 CLP 21,662 CLP 37
10Y P/E Exit 10,650 CLP 17,092 CLP 25,007 CLP 35
Earnings-Based
Graham-Dodd 7,128 CLP 22,467 CLP 29,918 CLP 54
Lynch FV 4,924 CLP 7,034 CLP 9,144 CLP 50
PEG = 1.0 4,924 CLP 7,034 CLP 9,144 CLP 46
EPV 9,479 CLP 11,276 CLP 12,873 CLP 59
Multiples
P/E Multiple 13,365 CLP 17,821 CLP 22,276 CLP 63
P/S Multiple 10,703 CLP 14,270 CLP 17,838 CLP 58
P/B Multiple 11,057 CLP 14,742 CLP 18,428 CLP 55
EV/EBIT 12,043 CLP 16,291 CLP 20,539 CLP 53
EV/EBITDA 9,707 CLP 13,177 CLP 16,647 CLP 54
EV/Revenue 9,288 CLP 13,569 CLP 17,850 CLP 43
Asset-Based
NCAV (Graham) 2,457 CLP 3,292 CLP 4,914 CLP 50
Growth DCF
Growth DCF 10,604 CLP 16,537 CLP 25,499 CLP 80
Rev-Margin DCF 9,360 CLP 15,396 CLP 22,361 CLP 74
Economic Profit
Residual Income 7,138 CLP 9,489 CLP 43,402 CLP 76
ROIC Compounder 10,268 CLP 13,444 CLP 17,292 CLP 72
Growth Earnings
Growth-Adj P/E 11,381 CLP 16,259 CLP 21,136 CLP 68

Widest divergence: Growth Earnings (16,259 CLP) versus Asset-Based (3,292 CLP). Highest evidence: Growth DCF (80).

Notify me when OXIQUIM reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 228B CLP
Revenue growth (YoY) -14.6%
Net margin 10.4%
Return on equity 19.0%
Free cash flow 22.9B CLP FY2025
P/E ratio 9,677.4
More key figures
Operating margin 12.0%
EPS (TTM) 1.24 CLP
Dividend yield 8.7%
EPS growth (YoY) -34.6%
Net debt 47.1B CLP FY2025

Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 62/100

Of which business quality 59 · Market factors (momentum, volatility) 83

Profitability 68
Margins and returns on capital today
Quality Growth 42
Are margins and returns improving?
Cashflow 25
Earnings quality: real cash, not paper profit
Fin. Strength 71
Balance sheet, leverage, solvency risk
Investment 81
Disciplined investing over empire-building
Low Volatility 97
Calm price path (market factor)
Momentum 68
Price trend over the last 3–12 months (market factor)
52W Momentum 95
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Oxiquim S.A. engages in the production and sale of resins for the wood board industry in Chile. It offers liquid petroleum gas, clean fuels, wood board, animal feed and nutrition, human food, food flexible packaging films, thermoplastic and compostable resins, paints, coating, and adhesives; industrial water, desalination, purification and treatment; …

Full company description

Oxiquim S.A. engages in the production and sale of resins for the wood board industry in Chile. It offers liquid petroleum gas, clean fuels, wood board, animal feed and nutrition, human food, food flexible packaging films, thermoplastic and compostable resins, paints, coating, and adhesives; industrial water, desalination, purification and treatment; pharmaceuticals and cosmetics, mining, detergents and cleaning, cellulose and paper, HPLC solvents and ACS reagents, and other products. The company also provides reception, storage, and dispatch services for liquid bulk, serving mining companies, LPG and fuel distributors, pulp mills, paint and coating manufacturers, and resins and adhesive producers. In addition, it is involved in the distribution and marketing of a range of chemicals, raw materials, and specialties for the productive industry; and marketing, sales and technical support, product development, supply chain and logistics, sourcing and procurement, mixing and formulation, packaging and drumming, and private labeling services. The company was founded in 1955 and is based in Santiago, Chile.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Oxiquim S.A reported revenue of 237B CLP in FY2025 versus 191B CLP in FY2021, a compound +5.5%/yr. Reported net income was 26.1B CLP in FY2025, compounding +6.0%/yr from FY2021.

Growth Quality 79/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
237B CLP
Latest YoY
+0.6%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−3.6%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+8.4%
Avg. growth/yr (11Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+4.9%
Revenue +5.5%/yr
FY21 191B CLP
FY22 265B CLP
FY23 215B CLP
FY24 235B CLP
FY25 237B CLP
Net income +6.0%/yr
FY21 20.7B CLP
FY22 29.1B CLP
FY23 23.9B CLP
FY24 26.3B CLP
FY25 26.1B CLP

Watch OXIQUIM: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Oxiquim S.A Fair Value". https://www.fairvalue-calculator.com/stock/OXIQUIM

Peer Group

Chemicals · 333 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 62 · Top 25%
Fair Value upside +19% · Top 25%
Return on equity (TTM) 19% · Top 25%
Return on assets 7% · Top 25%
Net margin (TTM) 10% · Top 25%
Operating margin (TTM) 12% · Above median
Revenue growth -15% · Bottom 25%
Dividend yield (TTM) 8.7% · Top 25%
Debt / equity 0.24× · Higher than median

Valuation Multiples vs Chemicals median · lower = cheaper

P/FCF 0.0× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 58 · sector 0
FUTURE 0 · sector 20
PAST 76 · sector 19
HEALTH 88 · sector 94
DIVIDEND 100 · sector 27

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).

Stock Price Fair Value vs Fair Value
BASF SE BASN 1,034 MXN 532.13 MXN -49%
Ningxia Baofeng Energy Group 600989 ¥20.32 ¥20.17 -1%
Zhejiang Juhua Co 600160 ¥42.85 ¥23.35 -46%
PT Barito Pacific Tbk, BRPT 1,690 IDR 1,628 IDR -4%
LG Chem, Ltd 051910 260,500 KRW 587,755 KRW +126%
Formosa Chemicals & Fibre Corporation 1326 66.10 TWD 6.79 TWD -90%
PTT Global Chemical Public Company PTTGC 35.50 THB 18.21 THB -49%
542812 542812 ₹4,369 ₹791.05 -82%
Indorama Ventures Public Company IVL 24.50 THB 17.95 THB -27%
Navin Fluorine International Limited NAVINFLUOR ₹8,650 ₹2,146 -75%

Compare Oxiquim S.A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Oxiquim S.A (OXIQUIM) overvalued or undervalued?
As of Jul 18, 2026, our model estimates a fair value of 14,742 CLP versus a price of 12,441 CLP, about +19% (undervalued).
What is the fair value of OXIQUIM?
Our model-based fair value for Oxiquim S.A is 14,742 CLP (as of Jul 18, 2026), built from audited fundamentals. The current price is 12,441 CLP.
What is the quality score of OXIQUIM?
Oxiquim S.A has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Oxiquim S.A (OXIQUIM)?
Oxiquim S.A reported trailing-twelve-month revenue of about 228B CLP (latest available figure, as of Jul 18, 2026).
What is the net profit margin of OXIQUIM?
The net profit margin of Oxiquim S.A is about 10.4%, meaning it keeps roughly 10.4% of revenue as net income. Based on the latest reported figures.
Does Oxiquim S.A pay a dividend?
Oxiquim S.A currently shows a dividend yield of about 8.72% relative to its recent price (as of Jul 18, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Oxiquim S.A and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.